Filing Flows › Health Care › Camp4 Therapeutics (CAMP)
Camp4 Therapeutics (CAMP) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Camp4 Therapeutics (CAMP) Q3 2026 earnings results →
Q3 2026 Revenue up 139% year over year to $1.9M · operating margin -738.8%
Camp4 Therapeutics made $1.9M in Q3 2026 (+139% Y/Y). Operating margin -738.8%, net loss $29.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.9M in Q3 2026, up 139% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $14.0M, an operating margin of -738.8%. Total costs grew 10% against revenue growth of 139%. The fastest-growing cost line was Research & development (+16%). The quarter ended with a net loss of $29.0M, narrower than the previous quarter's $33.5M loss. Net interest and other expense of $14.9M was the main reason.
Operating cash flow was −$8.2M. Non-cash charges added back $523K of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items added $18.2M. Capital expenditures of $740K exceeded it, leaving free cash flow of −$8.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $1.9M | +139% | -738.8% | −$29.0M | −$8.2M |
| Q2 2026 | 10-Q | Aug 13, 2026 | $1.8M | +19% | -752.1% | −$33.5M | −$12.7M |
| Q1 2026 | 10-Q | May 7, 2026 | $1.3M | +51% | n/m | −$18.3M | −$11.0M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $795K | — | n/m | −$15.1M | −$11.2M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $1.5M | — | -870.3% | −$12.6M | −$10.3M |
| Q1 2025 | 10-Q | May 13, 2025 | $858K | — | n/m | −$12.4M | −$14.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Camp4 Therapeutics
We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. Our lead product candidate, CMP-002, has the potential to be the first disease-modifying therapy for the treatment of synaptic Ras GTPase activating protein 1 (“SYNGAP1”)-related disorder, or SYNGAP1, a severe developmental and epileptic encephalopathy (“DEE”) characterized by seizures, developmental delays, and cognitive impairments. SYNGAP1 is caused by haploinsufficiency of the SYNGAP1 gene, where mutation of one gene copy results in a reduction in functional SYNGAP protein levels of up to 50%.
In its own words, from its 10-K, filed Mar 5, 2026.
Camp4 Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +139% against the peers' median +10%. Operating margin: -738.8% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CAMP Camp4 Therapeutics | Q3 2026 | $1.9M | +139% | -738.8% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Camp4 Therapeutics 10-Q on SEC EDGAR · CIK 1736730 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns CAMP and who is buying
More on CAMP
- How Camp4 Therapeutics makes money: revenue by segment
- Camp4 Therapeutics next earnings date and what analysts expect
- Camp4 Therapeutics stock forecast, price target and fair value
- Who owns Camp4 Therapeutics stock: holders, funds and Congress trades
- Camp4 Therapeutics guidance and outlook
- Camp4 Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q3 2025 results · Q2 2025 results · Q1 2025 results